7/15/2015 Biotech manufacturer Celgene is making an earnest push to become one of the industry’s leaders following a wave of transactions aimed at increasing long-term sustainability. Celgene’s current success is largely based on the popularity of its breakthrough cancer drug, Revlimid; however Celgene is attempting to set itself up for future growth when Revlimid’s patent
7/8/2015 The U.S. Food and Drug Administration (FDA) released the results of a 1093-patient study on Tuesday of drugmaker, Eli Lilly’s experimental drug necitumumab, aimed at treating a certain form of lung cancer. The information comes as the FDA will be conducting a panel of outside experts on Thursday, July 9th that will review the
5/29/2015 Despite the ongoing FBI investigation of Johnson & Johnson’s manufacturing division, Ethicon, and a strong Food and Drug Administration (FDA) warning issued last year, power morcellators are still legal. The device grinds up tissue mass, and is then removed through a series of small incisions. The device, which is used to provide minimally invasive
The recent approval of a drug for use in combating leukemia by the US Food and Drug Administration has shed light on the relatively controversial, albeit common practice by that organization of using surrogate markers of efficacy for determining the benefit of a given drug or therapy. Some believe this constitutes a low bar for
The first thing any industry faced with negative scientific evidence does is form a trade group. And the first thing that trade group does is gin up “scientific” evidence that claims the industry is being falsely maligned. The asbestos industry did (and does) it, and of course so did the tobacco industry. Now, it’s the
In my day job, I’m an asbestos and mesothelioma lawyer. As part of that job, I have to keep track of the various significant events related to asbestos and mesothelioma. I have a database of hundreds of scientific articles, corporate studies, etc. that track the development of the knowledge that asbestos is harmful. I’ve decided not